Thursday, April 25th | 17 Nisan 5784

Subscribe
May 26, 2016 1:17 pm
0

Israeli Firm Successfully Tests 3-D Printing for Stem Cells

× [contact-form-7 404 "Not Found"]

avatar by JNS.org

A new breakthrough in 3-D printing by an Israeli company could lead to the ability to print tissues and organs. (Illustrative photo). Photo: United States of America Kristopher Radder/U.S. Navy via Wikimedia Commons.

A new breakthrough in 3-D printing by an Israeli company could lead to the ability to print tissues and organs. (Illustrative photo). Photo: United States of America Kristopher Radder/U.S. Navy via Wikimedia Commons.

JNS.org – The Israeli 3-D printing firm Nano Dimension Ltd. has successfully tested a 3-D bioprinter for stem cells, which is a first step on the way to the ability to print tissues and organs. The laboratory trial, conducted with the Israeli biotech firm Accellta Ltd., showed that the company’s adapted printer could quickly make a large amount of high-resolution cells.

“3-D printing of living cells is a technology that is already playing a significant role in medical research, but in order to reach its full potential, for the field to evolve further, there is a need to improve printing speeds, print resolution, cell control, and viability, as well as cell availability and bio-ink technologies. By combining our high-speed, high-precision inkjet capabilities with Accellta’s stem cell suspension technologies and induced differentiation capabilities led by a world-renowned group of experienced engineers and scientists, we can enable 3-D printing at high resolution and high volumes,” said Nano Dimension CEO Amit Dror, Reuters reported.

“We hope and believe that this will bring the mutual capabilities and know-how of both companies to create 3-D bioprinting solutions that combine a high-precision, high-throughput printer with dedicated bio-ink technologies, derived from stem cells,” said Dr. Itzchak Angel, chairman and CEO of Accellta.

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

Algemeiner.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.